Selected article for: "case fatality rate and clinical investigation"
Author: Gao, Hainv; Yao, Hangping; Yang, Shigui; Li, Lanjuan
Title: From SARS to MERS: evidence and speculation
  • Cord-id: foolgmqj
  • Document date: 2016_12_23
    • ID: foolgmqj
    Snippet: The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths.Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this
    Document: The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths.Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this review, we summarize the recent findings in the field of MERS-CoV, especially its molecular virology, interspecies mechanisms, clinical features, antiviral therapies, and the further investigation into this disease. As a newly emerging virus, many questions are not fully answered, including the exact mode of transmission chain, geographical distribution, and animal origins. Furthermore, a new protocol needs to be launched to rapidly evaluate the effects of unproven antiviral drugs and vaccine to fasten the clinical application of new drugs.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein function and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • activity test and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acute pneumonia and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute pneumonia and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute pneumonia and lymphocyte activation: 1
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response activation: 1, 2
    • acute sars cov respiratory syndrome coronavirus and low dosage: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lymphocyte activation: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lymphocyte activation: 1, 2, 3, 4, 5
    • low mortality and lymphocyte activation: 1